Drug development of lyso-thermosensitive liposomal doxorubicin: Combining hyperthermia and thermosensitive drug delivery

We review the drug development of lyso-thermosensitive liposomal doxorubicin (LTLD) which is the first heat-activated formulation of a liposomal drug carrier to be utilized in human clinical trials. This class of compounds is designed to carry a payload of a cytotoxic agent and adequately circulate in order to accumulate at a tumor that is being heated. At the target the carrier is activated by heat and releases its contents at high concentrations. We summarize the preclinical and clinical experience of LTLD including its successes and challenges in the development process. (C) 2021 The Author(s). Published by Elsevier B.V.

Automated summary

LTLD is the first heat-activated formulation of a liposomal drug carrier utilized in human clinical trials, designed to release therapeutic drugs at heated tumors. The drug has shown some successes in preclinical and clinical trials, but also encountered challenges in the development process.